Arch Therapeutics (OTCMKTS:ARTH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “
A number of other brokerages have also recently commented on ARTH. ValuEngine cut Arch Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. HC Wainwright set a $3.00 price target on Arch Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Finally, Ifs Securities upgraded Arch Therapeutics from an “outperform” rating to a “strong-buy” rating in a research report on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $2.17.
WARNING: “Arch Therapeutics (ARTH) Downgraded by Zacks Investment Research” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/02/23/arch-therapeutics-arth-downgraded-by-zacks-investment-research.html.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.